ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
2021年04月28日 11時00分
Source:
Eisai
埼玉りそな銀行とエーザイ、埼玉県における認知症との共生と予防に向け業務提携を締結
認知症エコシステムの構築
東京, 2021年04月28日 - (JCN Newswire) - りそなグループの株式会社埼玉りそな銀行(本社:埼玉県、社長:福岡 聡、以下 埼玉りそな銀行)とエーザイ株式会社(本社:東京都、代表執行役CEO:内藤 晴夫、以下 エーザイ)は、埼玉県民の皆さまが末永く健康で安心して暮らせる地域社会を実現するため、本日、認知症の共生と予防に取り組むエコシステム(以下、「認知症エコシステム」)構築に向けた業務提携契約を締結したことをお知らせします。
埼玉県は全国トップクラスのスピードで高齢化が進行すると見込まれており、認知症の共生と予防に向けた取り組みが大きな課題のひとつです。埼玉りそな銀行とエーザイは、本業務提携を通じて埼玉りそな銀行が有する埼玉県内のお客さま基盤・ネットワークと、エーザイの認知症領域における創薬活動や疾患啓発活動の豊富な経験知を融合させた認知症エコシステムを構築し、県民ならびに県内企業の皆さまの健康生活のサポートおよび持続可能な地域社会づくりを行います。
その取り組みの第一弾として、埼玉りそな銀行が取り扱う投資信託「埼玉りそな・グローバルバランス・プラスESG~SaitamaDGs~」※1のご契約者さまに、エーザイのブレインパフォーマンス(脳の健康度)セルフチェックツール「のうKNOWTM」(ノウノウ、非医療機器)※2を提供します。お客さまに埼玉県債などへの投資を通じた資産形成と地域貢献の機会を提供するとともに、ブレインパフォーマンスの定期的なチェックと生活習慣の改善を通じた脳の健康維持により、安心した暮らしの実現をサポートします。
さらに、埼玉りそな銀行とエーザイは、認知症エコシステムを通じて県内自治体や企業、大学、公共機関等と連携し、県民の皆さまの不安の軽減・解消や豊かな老後生活の実現、県内企業の健康経営の実現など、持続可能な安心して暮らせる地域社会づくりに向けた価値共創をめざしてまいります。
本リリースの詳細は下記をご参照ください。
https://www.eisai.co.jp/news/2021/news202132.html
概要:エーザイ株式会社
詳細は www.eisai.co.jp をご覧ください。
Source: Eisai
セクター: バイオテック
Copyright ©2026 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
Sumitomo Heavy Industries and NEC to develop system capable of identifying and reporting near-miss incidents
Mar 25, 2026 14:27 JST
NEC Orchestrating Future Fund Invests in U.S.-based AGI7, Provider of "Alpha Vision" Platform for Autonomous Operations of AI Agents in Physical Spaces
Mar 25, 2026 13:17 JST
Fujitsu and The University of Osaka develop new technologies for chemical material energy calculations on early-FTQC quantum computers
Mar 25, 2026 10:58 JST
HIES introduces plant-based lubricant that reduces air compressor lifecycle CO(2) emissions by 40%
Mar 24, 2026 18:07 JST
Fujitsu and Umios conduct joint pilot project for electronic traceability system to visualize seafood distribution
Mar 24, 2026 14:01 JST
Fujitsu-developed traffic simulation system utilized in Maebashi City's public transportation planning
Mar 23, 2026 14:24 JST
Hitachi Receives the 2026 Catalyst Award, a Global Recognition for Building an Inclusive Organization
Mar 23, 2026 11:49 JST
Results from Real-World, Long-Term Treatment Persistence with LEQEMBI(R) (lecanemab-irmb) in the United States Presented at AD/PD(TM) 2026
Mar 23, 2026 11:19 JST
Honda to Expand Motorcycle Production Capacity in India by Adding New Motorcycle Production Line to its Second Plant
Mar 19, 2026 18:32 JST
Honda WN7 Electric Motorcycle Wins Gold Award at iF DESIGN AWARD 2026
Mar 19, 2026 18:16 JST
Hitachi, The University of Technology Sydney and NTT DATA Sign MoU to Accelerate Green Transformation in Australia
Mar 19, 2026 18:08 JST
MHI Thermal Systems Expands Lineup of Air-to-Water Heat Pumps for the European Market
Mar 19, 2026 15:14 JST
DENSO Invests in Next Core Technologies to Enhance Performance of Electric Vehicles
Mar 19, 2026 14:25 JST
NEC Completes Design of Equipment for Technology Demonstration Satellite Aimed at Creating Japan's First Optical Communication Satellite Constellation
Mar 19, 2026 11:05 JST
Eisai: Regarding Discontinuation of Administration of "Tazverik(R) Tablets 200mg" (tazemetostat hydrobromide)
Mar 19, 2026 10:54 JST
Hitachi is recognized as one of the World's Most Ethical Companies(R) for a second consecutive year
Mar 19, 2026 10:41 JST
MHI Commends Outstanding Examples of Implementing its New Management Policy "ITO"
Mar 18, 2026 13:09 JST
FILMART and EntertainmentPulse open today
Mar 17, 2026 21:41 JST
TANAKA PRECIOUS METAL GROUP Provides Medals, Commemorative Items, and Trophies as Category Sponsor (Awards Ceremonies) for the LIGA.i Blind Soccer Top League 2025
Mar 17, 2026 21:00 JST
Eisai Established the Global Capability Centre in Visakhapatnam, India, to Standardize Global IT Infrastructure Operations and Digital Transformation
Mar 17, 2026 19:49 JST
More Latest Release >>
Related Release
Results from Real-World, Long-Term Treatment Persistence with LEQEMBI(R) (lecanemab-irmb) in the United States Presented at AD/PD(TM) 2026
3/23/2026 11:19:00 AM JST
Eisai: Regarding Discontinuation of Administration of "Tazverik(R) Tablets 200mg" (tazemetostat hydrobromide)
3/19/2026 10:54:00 AM JST
Eisai Established the Global Capability Centre in Visakhapatnam, India, to Standardize Global IT Infrastructure Operations and Digital Transformation
3/17/2026 7:49:00 PM JST
Eisai Launches Awareness Campaign on Importance of Sleep Through "Pokemon Sleep" Collaboration
3/12/2026 5:21:00 PM JST
Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD(TM) 2026 Annual Meeting
3/11/2026 12:07:00 PM JST
WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
3/2/2026 9:49:00 AM JST
Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Novel Orexin Receptor Agonist E2086 for Narcolepsy
2/16/2026 2:03:00 PM JST
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Designated for Priority Review in China
2/10/2026 1:34:00 PM JST
Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan
2/6/2026 11:31:00 AM JST
FDA Accepts LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
1/26/2026 11:37:00 AM JST
More Press release >>